PLAGL1

Across TCGA pan-cancer cohorts, PLAGL1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLAGL1 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PLAGL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLAGL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and READ are the cancer types where PLAGL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.068	0.674	<.001	31	view →
UCEC	DFS	Median	All	1.000	0.619	.006	18	view →
READ	DFS	Median	III,IV	0.255	0.757	.008	15	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
LUAD	OS	Median	All	0.338	0.834	.004	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLAGL1–ACC (DFS)

Open the ACC breakdown →